A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Subjects
Latest Information Update: 19 Mar 2024
At a glance
- Drugs DXP-593 (Primary) ; DXP-604 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors BeiGene
- 27 Jul 2021 Status changed from active, no longer recruiting to completed.
- 20 May 2021 Planned primary completion date changed from 1 Mar 2021 to 21 May 2021.
- 20 May 2021 Status changed from recruiting to active, no longer recruiting.